The Phelan-McDermid Syndrome (22q13.3 Deletion Syndrome) drugs in development market research report provides comprehensive information on the therapeutics under development for Phelan-McDermid Syndrome (22q13.3 Deletion Syndrome), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Phelan-McDermid Syndrome (22q13.3 Deletion Syndrome). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Phelan-McDermid Syndrome (22q13.3 Deletion Syndrome) and features dormant and discontinued products.
GlobalData tracks 12 drugs in development for Phelan-McDermid Syndrome (22q13.3 Deletion Syndrome) by 12 companies/universities/institutes. The top development phase for Phelan-McDermid Syndrome (22q13.3 Deletion Syndrome) is preclinical with four drugs in that stage. The Phelan-McDermid Syndrome (22q13.3 Deletion Syndrome) pipeline has 12 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Phelan-McDermid Syndrome (22q13.3 Deletion Syndrome) pipeline products market are: Oryzon Genomics, Neuren Pharmaceuticals and PYC Therapeutics.
The key targets in the Phelan-McDermid Syndrome (22q13.3 Deletion Syndrome) pipeline products market include SH3 And Multiple Ankyrin Repeat Domains Protein 3, Translocator Protein, and Amine Oxidase [Flavin Containing] B.
The key mechanisms of action in the Phelan-McDermid Syndrome (22q13.3 Deletion Syndrome) pipeline product include SH3 And Multiple Ankyrin Repeat Domains Protein 3 Activator with three drugs in Preclinical. The Phelan-McDermid Syndrome (22q13.3 Deletion Syndrome) pipeline products include three routes of administration with the top ROA being Oral and four key molecule types in the Phelan-McDermid Syndrome (22q13.3 Deletion Syndrome) pipeline products market including Small Molecule, and Synthetic Peptide.
Phelan-McDermid Syndrome (22q13.3 Deletion Syndrome) overview
Phelan-McDermid syndrome, also called 22q13 deletion syndrome, is a genetic disorder caused by deletion of part of chromosome 22 or a defect in a gene called SHANK3. Symptoms can include intellectual disability, motor skill deficits, delayed or absent speech, autism spectrum disorder, and minor dysmorphic features.
For a complete picture of Phelan-McDermid Syndrome (22q13.3 Deletion Syndrome)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
